



Novel Pharmaceutical and Pharmacological Strategies to Induce Autophagy

Guest Editors:

Prof. Dr. Giovanni Piccoli

Department of Cellular,
Computational and Integrative
Biology (CIBIO), University of
Trento, 38123 Trento, Italy

Dr. Daniela Arosio

Istituto di Scienze e Tecnologie
Chimiche “Giulio Natta” (SCITEC),
National Research Council (CNR),
20133 Milan, Italy

Dr. Pierfausto Seneci

Chemistry Department,
Università Statale di Milano, Via
Golgi 19, I-20133 Milan, Italy

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editors

Both genetic and molecular evidence have implicated autophagy in the pathogenesis of neurodegenerative disorders. Thus, the pharmacological induction of autophagy may result a potential therapeutic approach relevant to neurodegenerative disorders. Autophagy inducers rapamycin and trehalose proved to be effective *in vitro* and *in vivo*. However, those compounds have a limited clinical applicability because of safety and pharmacokinetic issues. Meanwhile, new autophagy-connected molecular targets were identified and validated, and drug discovery efforts targeted against them are appearing at a fast pace. Clearly, autophagy induction may be a promising therapeutic opportunity, but clinically relevant drugs are still to be discovered.

The Special Issue invites research on new strategies to induce autophagy in therapeutic, authentic models. Studies on the identification of natural and synthetic autophagy inducers from HTS campaigns, on the rational design and structure-activity relationships of small molecule autophagic inducers, biologicals, nanocarriers, alternative systems to deliver putative autophagic drugs, and preclinical evaluation of promising leads, are welcomed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
[@MDPIpharma](https://twitter.com/MDPIpharma)